Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.18), $0.85 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $402.1 million versus the consensus estimate of $388.57 million.

"The first quarter demonstrated Exact Sciences is well-positioned for growth today and into the future," said Kevin Conroy, Chairman and CEO. "Our Cologuard® and Oncotype® tests help people in need of answers, including those who have been vulnerable during the pandemic. We plan to bring additional solutions to patients throughout the course of their diagnosis and treatment."

GUIDANCE:

Exact Sciences sees Q2 2021 revenue of $1.69-1.735 billion, versus the consensus of $1.72 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.